# Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

> **NCT00532311** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 411 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Lapaquistat acetate and stable statin therapy
- **DRUG:** Stable statin therapy

## Key facts

- **NCT ID:** NCT00532311
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 411 (ACTUAL)
- **Why stopped:** Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents
- **Last updated:** 2016-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532311, "Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00532311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*